


**EXAMINER'S AMENDMENT**

**Amendments to the Claims**

/CC/  
OK enter  
1/21/10


Claim 1 (Currently amended): A compound of Formula I:



I

where:

W is a ring selected from the group consisting of:



Y is N or C-R<sup>1</sup>;

R is C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, (C<sub>1</sub>-C<sub>4</sub> alkylene)-(C<sub>3</sub>-C<sub>6</sub> cycloalkyl), SO<sub>2</sub>R<sup>7</sup>, phenyl, or benzyl optionally substituted on the phenyl ring with one or two substituents selected from halo:

$R^1$  is hydrogen, amino, or methyl:

$R^2$  is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

$R^3$  is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, trifluoromethyl, or phenyl optionally substituted with one or two substituents independently selected from the group consisting of halo, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)thio, 1-(pyrrolidin-1-yl)eth-2-oxy, and 1-(piperidin-1-yl)eth-2-oxy; or

$R^2$  and  $R^3$  taken together form either the group  $-(CH_2)_n-$  where  $n$  is 2 or 3 or the group  $-CH=CH-$ ;

R<sup>4</sup> is phenyl optionally substituted with one or two substituents independently selected from the group consisting of halo and trifluoromethyl;

R<sup>5</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from the group consisting of halo, trifluoromethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)thio, 1-(pyrrolidin-1-yl)eth-2-oxy, and 1-(piperidin-1-yl)eth-2-oxy;

R<sup>6</sup> is hydrogen or ethoxymethyl;

R<sup>7</sup> is C<sub>4</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or dialkylamino where each alkyl group is independently selected from C<sub>4</sub>-C<sub>4</sub> alkyl;

R<sup>8</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

provided that:

(a) when W is (i), then at least one of R<sup>2</sup> and R<sup>3</sup> is hydrogen or methyl; and

(b) R may be SO<sub>2</sub>R<sup>7</sup> only when either W is isoxazole (vii) or Y is N, or R may be SO<sub>2</sub>R<sup>7</sup>

/CC/ when both W is isoxazole (vii) and Y is N; when W is imidazole (i), R is C<sub>1</sub>-C<sub>8</sub> alkyl, R<sub>2</sub> is hydrogen, R<sub>3</sub> is phenyl substituted with one or two substituents selected from halo; or a pharmaceutically acceptable salt thereof.

Claim 2 (Previously Presented): A compound of Claim 1, where W is a ring of formula (i).

Claim 3 (Original): A compound of Claim 2, where Y is C-R<sup>1</sup> and R<sup>1</sup> is amino.

Claim 4 (Original): A compound of Claim 3, where R is C<sub>1</sub>-C<sub>8</sub> alkyl.

Claim 5 (Previously Presented): A pharmaceutical formulation comprising a compound Claim 1 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

Claims 6-7 (canceled)